How Long Does Saxenda Take to Work?

How long does Saxenda take to work is a common question for anyone starting this injectable weight-management treatment. Saxenda (liraglutide 3 mg) begins influencing appetite-regulating pathways from the first dose, but meaningful weight loss typically becomes noticeable after several weeks, once the full therapeutic dose of 3 mg daily is reached. The dose-escalation schedule takes approximately five weeks, and NICE guidance (TA664) defines a clinically meaningful response as at least 5 per cent body weight loss after 12 weeks at the full dose. Individual results vary depending on diet, activity levels and overall health.

How long does Saxenda take to start working?

Saxenda begins acting on appetite pathways from the first dose, but the full therapeutic effect is generally expected only once the 3 mg maintenance dose is reached after approximately five weeks of escalation.

Saxenda (liraglutide 3 mg) begins acting on appetite-regulating pathways from the first dose, though meaningful weight loss typically becomes noticeable after several weeks of treatment; individual responses vary considerably and the timeframe cannot be stated precisely for any one person. Saxenda is a glucagon-like peptide-1 (GLP-1) receptor agonist, licensed in the UK by the MHRA for chronic weight management in adults with a body mass index (BMI) of 30 kg/m² or above, or 27 kg/m² or above in the presence of at least one weight-related comorbidity such as type 2 diabetes or hypertension (Saxenda SmPC, section 4.1).

The medicine works by mimicking the natural GLP-1 hormone, which acts on receptors in the brain to reduce appetite, slow gastric emptying and promote a feeling of fullness after eating. Because of this mechanism, some people notice reduced hunger within the first one to two weeks, even before significant weight change is visible on the scales.

Saxenda is introduced gradually through a dose-escalation schedule to minimise gastrointestinal side effects. The starting dose is 0.6 mg once daily, increasing in weekly steps up to the full therapeutic dose of 3 mg once daily, as set out in the Saxenda SmPC section 4.2. This escalation period lasts approximately five weeks, and the full appetite-suppressing effect is generally expected only once the maintenance dose is reached and tolerated, though this varies between individuals.

Saxenda is intended to complement a reduced-calorie diet and increased physical activity, not to replace them. The medicine supports behavioural change rather than acting as a standalone solution, and individual responses vary considerably depending on a range of personal and clinical factors.

What results can you realistically expect week by week?

Appetite reduction may begin in weeks one to five during dose escalation, with more consistent weight loss from week six onwards; NICE TA664 defines a meaningful response as at least 5 per cent body weight loss after 12 weeks at the full dose.

Clinical evidence suggests that people using Saxenda alongside lifestyle changes can expect gradual, progressive weight loss over several months, with the most meaningful changes typically seen after the full dose is established. In the pivotal SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., New England Journal of Medicine, 2015), participants using liraglutide 3 mg lost an average of approximately 8 per cent of their body weight over 56 weeks, compared with around 2.6 per cent in the placebo group. Individual results vary, and not everyone achieves this average.

A broad week-by-week picture for many people looks like this:

• Weeks 1 to 5: Dose escalation phase. Appetite reduction may begin, but weight loss is often modest. Gastrointestinal side effects such as nausea are most common during this period.

• Weeks 6 to 12: At the full 3 mg dose, appetite suppression becomes more consistent and measurable weight loss may begin for those responding well, though the amount varies between individuals.

• Weeks 12 to 24: Continued steady loss is typical for those responding well. The Saxenda SmPC (section 4.2) and NICE guidance (TA664) both state that a clinically meaningful response is defined as at least 5 per cent weight loss after 12 weeks at the full dose.^[1][2]

• Beyond 24 weeks: Weight loss may plateau as the body adapts. Ongoing adherence to dietary and activity goals remains essential to sustain progress.

NICE TA664 recommends that treatment should be reviewed at week 16 (12 weeks at the full dose). If a person has not lost at least 5 per cent of their initial body weight by that point, Saxenda should ordinarily be discontinued, as continued use is unlikely to be beneficial. Individual trajectories vary and plateaus are common; this timeline is a guide, not a guarantee.

What factors affect how quickly Saxenda works for you?

Dietary adherence, physical activity, starting BMI, gastrointestinal tolerance and concurrent medications all influence how quickly and effectively Saxenda produces weight loss.

Several individual factors influence how quickly and how effectively Saxenda produces weight loss, meaning results vary considerably from person to person. Understanding these variables can help set realistic expectations and support a more productive conversation with a prescriber or pharmacist.

Dietary adherence is one of the most significant determinants. Saxenda reduces appetite but does not eliminate the impact of calorie intake entirely. People who make consistent dietary changes alongside treatment tend to see faster and greater results than those who rely on the medicine alone.

Physical activity levels also play a role. Regular movement supports a calorie deficit and helps preserve lean muscle mass during weight loss, both of which contribute to better outcomes.

Starting BMI and metabolic health can influence the rate of response. People with insulin resistance, type 2 diabetes or other metabolic conditions may find that weight loss progresses differently; a prescriber can advise on what to expect based on individual circumstances.

Gastrointestinal tolerance affects how quickly the dose can be escalated. Those who experience significant nausea or vomiting may need to remain on a lower dose for longer, delaying the full therapeutic effect.

Medication interactions and other health conditions should always be discussed with a prescriber. The Saxenda SmPC (section 4.5) and the BNF entry for liraglutide set out relevant interactions; medicines affecting gut motility or blood glucose are among those that may require consideration. Your prescriber or pharmacist can advise on any medicines you are already taking.

Bolt Pharmacy is a GPhC-registered online pharmacy in Great Britain offering online weight-management consultations, with prescriber review and pharmacist support, where a range of treatment options may be considered based on individual clinical suitability. Consistent follow-up with a healthcare professional throughout treatment helps identify early whether Saxenda is working as expected and whether any adjustments are needed.

Side effects to be aware of while your body adjusts

Nausea, vomiting, diarrhoea and abdominal discomfort are the most common side effects, occurring mainly during dose escalation and usually improving as the body adjusts to each increase.

The most common side effects of Saxenda occur during the dose-escalation phase and typically affect the gastrointestinal system, including nausea, vomiting, diarrhoea, constipation and abdominal discomfort. These effects are usually mild to moderate in severity and tend to improve as the body adjusts to each dose increase over the five-week escalation period (Saxenda SmPC, sections 4.4 and 4.8).

To reduce the likelihood of nausea, it can help to:

• Eat smaller, lower-fat meals

• Avoid lying down immediately after eating

• Stay well hydrated throughout the day

• Inject Saxenda at the same time each day, as instructed in the patient information leaflet

If vomiting or diarrhoea is persistent and you are unable to keep fluids down, there is a risk of dehydration, which can in turn affect kidney function. If you cannot maintain adequate fluid intake, contact your GP or call NHS 111 for advice promptly; do not wait for your next scheduled appointment.

Hypoglycaemia (low blood sugar) is a risk particularly for people also taking sulphonylureas or insulin for type 2 diabetes. Saxenda itself has a low risk of causing hypoglycaemia when used alone, but the combination with other glucose-lowering medicines requires careful monitoring.

Pancreatitis has been reported in people using liraglutide, including post-marketing reports of necrotising pancreatitis and reports with a fatal outcome (Saxenda SmPC, section 4.4). The SmPC does not quantify the risk magnitude. Persistent, severe abdominal pain that may radiate to the back should be assessed promptly by a doctor. Contact your GP if you experience this symptom, or call NHS 111 if you need urgent advice outside of surgery hours.

Pregnancy and breastfeeding: Saxenda is not recommended during pregnancy or breastfeeding.^[1][6] If you become pregnant while taking Saxenda, stop the medicine and contact your prescriber promptly. People of childbearing potential should discuss contraception with their prescriber before starting treatment (Saxenda SmPC, section 4.6).

Injection site reactions such as redness, bruising or itching can occur. Rotating the injection site between the abdomen, thigh and upper arm helps minimise this.^[1]

Suspected side effects from Saxenda can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. Reporting helps the MHRA monitor the safety of medicines in real-world use.

When should you speak to a doctor if Saxenda isn't working?

Speak to your prescriber if you have not lost at least 5 per cent of your body weight after 12 weeks at the full 3 mg dose, or sooner if you experience severe abdominal pain, persistent vomiting, signs of allergic reaction or irregular heartbeat.

You should speak to your GP or prescriber if you have been taking Saxenda at the full dose of 3 mg for 12 weeks and have not lost at least 5 per cent of your starting body weight. This is the threshold set out in the Saxenda SmPC (section 4.2) and reflected in NICE guidance (TA664) to determine whether continued treatment is appropriate. Continuing Saxenda beyond this point without a meaningful response is unlikely to produce benefit and exposes you to ongoing side effects and cost without clinical justification.

There are also specific symptoms that warrant prompt medical attention:

• Severe or persistent abdominal pain, which may indicate pancreatitis and should be assessed by a GP or, if severe and sudden, via NHS 111 for urgent advice

• Persistent vomiting or diarrhoea with inability to keep fluids down, which can lead to dehydration and affect kidney function; seek prompt medical advice if this occurs^[1]

• Signs of a serious allergic reaction, including swelling of the face, lips, tongue or throat, difficulty breathing, or a widespread rash. Call 999 immediately if you experience these symptoms, as this is a medical emergency

• Rapid or irregular heartbeat, which has been reported with liraglutide (Saxenda SmPC, section 4.^[6][9]8). Discuss this with your GP; seek urgent advice if it is accompanied by other concerning symptoms

• Symptoms of gallbladder problems, such as pain in the upper right abdomen, fever or jaundice, as GLP-1 receptor agonists have been associated with gallstones^[8]

If Saxenda is not tolerated due to persistent side effects, or if it is discontinued because of insufficient response, a prescriber can discuss alternative licensed options for weight management. It is also worth reviewing lifestyle factors with a healthcare professional, as dietary and activity changes remain central to long-term weight management regardless of which treatment is used. Never stop or adjust your dose without first speaking to your prescriber.

Scientific References

1. Saxenda 6 mg/mL solution for injection in pre-filled pen – Summary of Product Characteristics.
2. Liraglutide for managing overweight and obesity – Technology Appraisal TA664.
3. Liraglutide | Drugs | BNF – NICE.
4. GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis including necrotising and fatal cases.
5. GLP-1 receptor agonists: reminder of the potential side effects and to be aware of the potential for misuse.
6. Saxenda – EPAR product information (PDF).
7. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (Pi-Sunyer et al.).
8. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases (He et al.).
9. Heart rate increases in liraglutide treated chronic heart failure patients (Tougaard et al.).

Frequently Asked Questions